Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 379 of 1,261
  1. US 10864168

    Bioactive delivery vehicles

    The Regents of the University of California · Granted Dec 15, 2020 · Expires Dec 10, 2040

    granted
  2. US 10864158

    Multilayer thin film drug delivery device and methods of making and using the same

    The Regents of the University of California · Granted Dec 15, 2020 · Expires Dec 10, 2040

    granted
  3. US 10863729

    Rodents having a humanized TMPRSS gene

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 15, 2020 · Expires Dec 10, 2040

    granted
  4. CA 3142348

    INHIBITEURS DE DOPAMINE-B-HYDROXYLASE

    BIAL PORTELA & CA SA [PT] · Granted Dec 10, 2020 · Expires Dec 5, 2040

    granted
  5. WO 2020246903

    INHIBITEURS DE DOPAMINE-B-HYDROXYLASE

    BIAL PORTELA & Cª S A [PT] · Granted Dec 10, 2020 · Expires Dec 5, 2040

    granted
  6. US 2020384125

    GENE EDITING FOR HEMOPHILIA A WITH IMPROVED FACTOR VIII EXPRESSION

    CRISPR THERAPEUTICS AG [CH] · Granted Dec 10, 2020 · Expires Dec 5, 2040

    granted
  7. US 10858432

    Antibodies specific to glycosylated PD-1 and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  8. US 10858323

    HDAC inhibitors for the treatment of diabetic peripheral neuropathy

    Regenacy Pharmaceuticals, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  9. US 10857184

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  10. US 10857231

    Formulations of VEG antagonist fusion proteins and method of manufacturing them

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  11. US 10858628

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  12. US 10857225

    Smallpox vaccine for cancer treatment

    Calidi Biotherapeutics, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  13. US 10857106

    Methods and products for treating and/or delaying onset of dysplastic lesions

    The Regents of the University of Colorado, a Body Corporate · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  14. US 10857137

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  15. US 10857161

    Non-hormonal steroid modulators of NF-kB for treatment of disease

    ReveraGen BioPharma, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  16. US 10858634

    Vaccines and pharmaceutical compositions against foot-and-mouth disease virus

    The Government of the United States of America, as represented by the Secretary of Homeland Security · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  17. US 10858633

    Method for producing foot-and-mouth disease virus (FMDV) viral proteins utilizing a modified FMDV 3C protease

    The Government of the United States of America, as represented by the Secretary of Homeland Security · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  18. US 10858642

    Immunogenic arginase peptides

    IO Biotech ApS · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  19. US 10857139

    Substituted diazaspiroalkanes as androgen receptor modulators

    The Regents of the University of California · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  20. US 10858658

    Compositions and methods for inhibiting gene expression of factor XII

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  21. US 10858657

    Methods for treating hypercholesterolemia

    Ionis Pharmaceuticals, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  22. US 10858627

    Regulation of mesodermal specification

    Regents of the University of Minnesota · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  23. US 10858436

    PSGL-1 modulators and uses thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  24. US 10858416

    Methods and compositions for modification of a HLA locus

    The Board of Regents of the University of Texas System · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.